Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

16.50

Today's Change

+2.10 (14.58%)

Day's Change

14.60 - 16.54

Trading Volume

1,078,654

Overview

Market Cap

2 Billion

Shares Outstanding

127 Million

Avg Volume

521,765

Avg Price (50 Days)

13.53

Avg Price (200 Days)

18.25

PE Ratio

17.44

EPS

0.95

Earnings Announcement

29-Jan-2025

Previous Close

14.40

Open

14.85

Day's Range

14.6 - 16.58

Year Range

12.02 - 25.95

Trading Volume

1,116,879

Price Change Highlight

1 Day Change

15.07%

5 Day Change

35.82%

1 Month Change

16.69%

3 Month Change

-3.04%

6 Month Change

-18.17%

Ytd Change

-33.24%

1 Year Change

29.96%

3 Year Change

830.90%

5 Year Change

544.75%

10 Year Change

962.18%

Max Change

190.19%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment